210
Participants
Start Date
January 26, 2016
Primary Completion Date
May 15, 2019
Study Completion Date
May 15, 2019
Tenofovir + Emtricitabine or Lamivudine + Zidovudine
TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
Tenofovir + Emtricitabine or Lamivudine + Raltegravir
TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
CHU Sourô Sanou, Bobo-Dioulasso
CHU Yalgado Ouedraogo, Ouagadougou
Centre de Prise en Charge et de Formation (CePReF), Association ACONDA, Abidjan
Centre Médical du Suivi des Donneurs de Sang (Blood Bank Medical Centre), Abidjan
CIRBA, Abidjan
o L'Unité de soins ambulatoires et de conseils (USAC), CHU de Treichville, Abidjan
Service des Maladies Infectieuses et Tropicales (SMIT), CHU de treichville, Abidjan
CHNU Fann, Dakar
ONG Espoirs Vie Togo (EVT), Lomé
ANRS, Emerging Infectious Diseases
OTHER_GOV